clinical trial · NCT06663332
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development, LLC·phase3·recruiting·n = 196
Crohns DiseaseColitis, UlcerativeArthritis, PsoriaticArthritis, JuvenileGuselkumab
brief summary
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
started
Oct 29, 2024
primary completion
Dec 12, 2031
completion
Dec 12, 2031
last updated
May 8, 2026
official title
A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol